Linked-Reads: Find the Answer to What's Been Missing

September 30, 2018

Organisms and biology are immensely complex, and to truly understand disease mechanisms, heritability, potential diagnoses, and development of therapies, we need access to more genomic information. Linked-Reads constructs long-range information from short-reads to provide access to hidden and inaccessible information. With Linked-Reads, researchers now have the power to resolve ambiguous single nucleotide variants, provide phasing and haplotype information, identify structural variants, and assemble genomes without the need for a reference sequence.

Spotlight

Oxford BioMedica

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. Our technology platforms include a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy.

Other Infographics
news image

RNA sequencing libraries

Infographic | April 7, 2020

As part of our In Focus on RNA sequencing for cancer research, we put together an infographic to provide top tips on the preparation of RNA sequencing libraries, the best metrics to use when analyzing your libraries and suggestions for efficient and effective kits for the preparation of each library type.

Read More
news image

Designing Genetic Circuit

Infographic | April 13, 2020

Near the turn of the millennium, James Collins and Stanislas Leibler independently undertook rather similar projects: design what would become synthetic biology’s seminal genetic circuits. And they came up with strikingly similar action plans—use E. coli to pair promoters with repressors that control one another’s behavior.

Read More
news image

What Paraspeckles Can Teach Us About Basic Cell Biology

Infographic | December 1, 2019

Discovering a new type of subnuclear body taught me how pursuing the unexpected can lead to new insights—in this case, about long noncoding RNAs and liquid-liquid phase separation in cells.

Read More
news image

The COVID-19 pandemic has swept the globe, yet many people still do not understand how it affects the body

Infographic | April 16, 2020

The COVID-19 pandemic has swept the globe, yet many people still do not understand how it affects the body. This infographic shows the events that occur following SARS-CoV-2 infection

Read More
news image

Merck’s 23 CRISPR Patents Leading the way in genome-editing technology

Infographic | April 7, 2020

CRISPR Integration: CRISPR/Cas9 System for insertion in eukaryotic cells Compositions and use of CRISPR/Cas9 to integrate a new sequence of DNA after cutting genomic DNA. CRISPR-chrom: Improves access to the genome so that CRISPR-driven edits can be done more efficiently.

Read More
news image

Next-Gen Genetics: Cancer Therapies Create Investment Prospects

Infographic | August 12, 2022

The field (gene therapy) is not standing still, it’s evolving rapidly. If we have this discussion again in 18 months’ time, I don't know what we’ll be using then.

Read More

Spotlight

Oxford BioMedica

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. Our technology platforms include a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy.

Events